MY201165A - Npra agonists, compositions, and uses thereof - Google Patents
Npra agonists, compositions, and uses thereofInfo
- Publication number
- MY201165A MY201165A MYPI2019005393A MYPI2019005393A MY201165A MY 201165 A MY201165 A MY 201165A MY PI2019005393 A MYPI2019005393 A MY PI2019005393A MY PI2019005393 A MYPI2019005393 A MY PI2019005393A MY 201165 A MY201165 A MY 201165A
- Authority
- MY
- Malaysia
- Prior art keywords
- fatty acyl
- natriuretic peptide
- compositions
- terminus
- integer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762475147P | 2017-03-22 | 2017-03-22 | |
| PCT/US2018/023491 WO2018175534A1 (en) | 2017-03-22 | 2018-03-21 | Npra agonists, compositions, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY201165A true MY201165A (en) | 2024-02-08 |
Family
ID=63585777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2019005393A MY201165A (en) | 2017-03-22 | 2018-03-21 | Npra agonists, compositions, and uses thereof |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20200017567A1 (https=) |
| EP (1) | EP3601314A4 (https=) |
| JP (2) | JP7126270B2 (https=) |
| KR (1) | KR102714599B1 (https=) |
| CN (1) | CN110603260B (https=) |
| AU (2) | AU2018239352A1 (https=) |
| BR (1) | BR112019019720A2 (https=) |
| CA (1) | CA3056433A1 (https=) |
| EA (1) | EA201992226A1 (https=) |
| IL (1) | IL269388B2 (https=) |
| MX (1) | MX2019010960A (https=) |
| MY (1) | MY201165A (https=) |
| PH (1) | PH12019550163A1 (https=) |
| SG (1) | SG11201908580XA (https=) |
| WO (1) | WO2018175534A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12440496B2 (en) | 2019-05-22 | 2025-10-14 | Merck Sharp & Dohme Llc | Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes |
| US20220281886A1 (en) * | 2019-05-22 | 2022-09-08 | Merck Sharp Dohme Corp. | Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes |
| JP2023530273A (ja) * | 2020-06-12 | 2023-07-14 | ファーマイン コーポレイション | Ｃ型ナトリウム利尿ペプチド及び癌の処置におけるその方法 |
| CN115803338A (zh) * | 2020-06-12 | 2023-03-14 | 药明公司 | C型利尿钠肽及其治疗急性肺损伤的方法 |
| WO2024086680A2 (en) | 2022-10-21 | 2024-04-25 | Eli Lilly And Company | Long-acting natriuretic peptides and uses thereof |
| WO2024094747A1 (en) | 2022-11-02 | 2024-05-10 | Novo Nordisk A/S | Cnp compounds |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3985722A (en) * | 1973-12-12 | 1976-10-12 | Ajinomoto Co., Inc. | Process for preparing N-higher aliphatic acyl derivatives of amino acids, peptides or proteins |
| FR2687156B1 (fr) * | 1992-02-12 | 1994-04-01 | Roussel Uclaf | Nouveaux derives peptidiques, procede de preparation et application a titre de medicaments de ces nouveaux derives. |
| CN1062311C (zh) * | 1996-12-27 | 2001-02-21 | 中国医学科学院基础医学研究所 | 人白细胞介素2衍生物与人心钠素衍生物的融合基因、其蛋白产物及应用 |
| US6319503B1 (en) * | 1998-02-19 | 2001-11-20 | Proteinix Company | Heat shock fusion-based vaccine system |
| JP4237375B2 (ja) * | 2000-03-31 | 2009-03-11 | アスビオファーマ株式会社 | 虚血性疾患の処置又は予防に用いる医薬組成物 |
| WO2004047871A2 (en) * | 2002-11-26 | 2004-06-10 | Nobex Corporation | Modified naturetic compounds, conjugates, and uses thereof |
| US20100310561A1 (en) * | 2007-06-06 | 2010-12-09 | Boehringer Ingelheim International Gmbh | Natriuretic fusion proteins |
| US7960336B2 (en) * | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
| JP2010536341A (ja) * | 2007-08-15 | 2010-12-02 | アムニクス， インコーポレイテッド | 生物学的に活性なポリペプチドの特性を改変するための組成物および方法 |
| EP2217620A2 (en) * | 2007-11-21 | 2010-08-18 | BioMarin Pharmaceutical Inc. | Variants of c-type natriuretic peptide |
| KR101350251B1 (ko) * | 2008-05-23 | 2014-01-14 | 다이이찌 산쿄 가부시키가이샤 | 목적 펩타이드의 혈장내 반감기 연장 작용을 가진 펩타이드 |
| PT2432489T (pt) * | 2009-05-20 | 2016-12-07 | Biomarin Pharm Inc | Variantes do péptido natriurético de tipo c |
| WO2012088608A1 (en) * | 2010-12-27 | 2012-07-05 | Enobia Canada Limited Partnership | Compositions comprising natriuretic peptides and methods of use thereof |
| CN103402534B (zh) * | 2011-02-23 | 2016-10-12 | 麦德林制药私人有限公司 | 用于治疗充血性心力衰竭的治疗方法 |
| EP2678028A2 (en) * | 2011-02-25 | 2014-01-01 | Medtronic, Inc. | Systems and methods for therapy of kidney disease and/or heart failure using chimeric natriuretic peptides |
-
2018
- 2018-03-21 CA CA3056433A patent/CA3056433A1/en active Pending
- 2018-03-21 EP EP18771099.1A patent/EP3601314A4/en active Pending
- 2018-03-21 SG SG11201908580X patent/SG11201908580XA/en unknown
- 2018-03-21 KR KR1020197031122A patent/KR102714599B1/ko active Active
- 2018-03-21 MY MYPI2019005393A patent/MY201165A/en unknown
- 2018-03-21 WO PCT/US2018/023491 patent/WO2018175534A1/en not_active Ceased
- 2018-03-21 MX MX2019010960A patent/MX2019010960A/es unknown
- 2018-03-21 CN CN201880028963.9A patent/CN110603260B/zh active Active
- 2018-03-21 BR BR112019019720A patent/BR112019019720A2/pt unknown
- 2018-03-21 AU AU2018239352A patent/AU2018239352A1/en not_active Abandoned
- 2018-03-21 JP JP2019551608A patent/JP7126270B2/ja active Active
- 2018-03-21 EA EA201992226A patent/EA201992226A1/ru unknown
- 2018-03-21 IL IL269388A patent/IL269388B2/en unknown
-
2019
- 2019-09-12 PH PH12019550163A patent/PH12019550163A1/en unknown
- 2019-09-20 US US16/577,947 patent/US20200017567A1/en active Pending
-
2022
- 2022-04-22 JP JP2022070710A patent/JP2022090049A/ja not_active Withdrawn
-
2025
- 2025-02-21 AU AU2025201270A patent/AU2025201270A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022090049A (ja) | 2022-06-16 |
| KR20190133201A (ko) | 2019-12-02 |
| AU2018239352A1 (en) | 2019-10-10 |
| KR102714599B1 (ko) | 2024-10-07 |
| EA201992226A1 (ru) | 2020-02-12 |
| AU2025201270A1 (en) | 2025-03-13 |
| IL269388B1 (en) | 2024-11-01 |
| PH12019550163A1 (en) | 2020-06-08 |
| WO2018175534A1 (en) | 2018-09-27 |
| EP3601314A1 (en) | 2020-02-05 |
| EP3601314A4 (en) | 2021-01-13 |
| BR112019019720A2 (pt) | 2020-04-28 |
| CN110603260A (zh) | 2019-12-20 |
| CA3056433A1 (en) | 2018-09-27 |
| JP2020511494A (ja) | 2020-04-16 |
| US20200017567A1 (en) | 2020-01-16 |
| IL269388A (en) | 2019-11-28 |
| JP7126270B2 (ja) | 2022-08-26 |
| MX2019010960A (es) | 2020-01-20 |
| SG11201908580XA (en) | 2019-10-30 |
| IL269388B2 (en) | 2025-03-01 |
| CN110603260B (zh) | 2023-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019550163A1 (en) | Npra agonists, compositions, and uses thereof | |
| MY193353A (en) | Anti-vegf protein compositions and methods for producing the same | |
| MX2021005482A (es) | Lípidos de 2,5-dioxopiperazina con porciones éster, tioéster, disulfuro y anhidrido intercaladas. | |
| JP2018505146A5 (https=) | ||
| BR112012017683A2 (pt) | Emulsões nutritivas compreendendo hmb de calcio e proteina soluvel | |
| PH12018501956A1 (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| CY1116627T1 (el) | Παραγωγα μεταστινης και χρηση αυτων | |
| CY1118676T1 (el) | Βελτιωμενη συνθεση ανασυσταμενου επιφανειοδραστικου η οποια περιεχει αναλογα της επιφανειοδραστικης πρωτεϊνης β (sp-b) και της επιφανειοδραστικης πρωτεϊνης c (sp-c) | |
| BR112012023421A2 (pt) | composição farmacêutica para tratamento de aumento de pressão intraocular | |
| SG10201810154WA (en) | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | |
| MX2009012675A (es) | Tensioactivos reconstituidos que tienen propiedades mejoradas. | |
| CO6400235A2 (es) | Tensiactivos reconstituidos que tienen propiedades mejoradas | |
| JOP20210326A1 (ar) | أجسام مضادة للمستقبل 1 لببتيد إدرار الصوديوم في البول وطرق استخدامها | |
| GEP20247670B (en) | 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents | |
| WO2018215525A8 (en) | Mic-1 compounds and uses thereof | |
| CY1117006T1 (el) | Ν-[4-(1Η-ΠΥΡΑΖΟΛΟ[3,4-b|ΠΥΡΑΖΙΝ-6-ΥΛ)-ΦΑΙΝΥΛ]-ΣΟΥΛΦΟΝΑΜΙΔΕΣ ΚΑΙ Η ΧΡΗΣΗ ΤΟΥΣ ΩΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΜΕΣΑ | |
| GEP20257757B (en) | Therapeutic derivatives of interleukin-22 | |
| MX378591B (es) | Intermedios para la sintesis de derivados de acido biliar, en particular, de acido obeticolico | |
| MX2021006726A (es) | Enlazadores. | |
| EA201000860A1 (ru) | С-с-алкилимидазолбисфосфонаты | |
| MX2020009555A (es) | Inhibidores selectivos de proteina arginina-metiltransferasa 5 (prmt5). | |
| ATE271866T1 (de) | Kombination von liponsäure und konjuensäuren zur behandlung diabetischer störungen | |
| MY209459A (en) | Peptide conjugates of microtubule-targeting agents as therapeutics | |
| CY1110644T1 (el) | 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις | |
| CL2022002293A1 (es) | Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- 5 (trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio. |